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Abstract
Immune checkpoint inhibitors (ICIs), though revolutionizing cancer care, are well known to cause a diverse array of
autoimmune side effects termed immune-related adverse events (IRAEs). ICI Myocarditis is a rare manifestation of IRAE
associated with high mortality. We report two cases of fulminant ICI myocarditis refractory to potent immunosuppressants. Our ﬁrst patient received pembrolizumab for lymphoma, small cell lung cancer and renal cell carcinoma. After 13
doses of ICIs, he developed fulminant myocarditis with concomitant lower-motor neuron type facial nerve palsy. Despite
receiving triple immunosuppressive therapies with pulse steroid, mycophenolate mofetil and basiliximab, his cardiac
condition progressively worsened and eventually died of heart failure. Our second patient received dual ICIs with
pembrolizumab and ipilimumab for inoperable hepatocellular carcinoma. Shortly after ﬁrst doses of ICIs, he developed
3M syndrome with the classically described triad of Myocarditis, Myositis and bulbar Myasthenia gravis. Despite
receiving pulse steroid, mycophenolate mofetil, tacrolimus, plasmapheresis and intravenous immunoglobulin, he had
persistent myocardial inﬂammation with elevated troponin level, and refractory bulbar myasthenia requiring mechanical
ventilation and nasogastric tube feeding. Our case series illustrates challenges with managing ICI myocarditis and its
associated clinical syndromes including the 3M syndrome. Given the wide application of ICIs, clinical trials as well as
preclinical studies are urgently needed to ﬁnd out the optimal therapy for ICI myocarditis. As early identiﬁcation of ICI
myocarditis allows prompt cessation of ICIs and initiation of immunosuppressants, which may potentially improve
cardiovascular outcome of these patients, it is also crucial to determine to optimal strategies for screening ICI myocarditis.
Keywords: Immune checkpoint inhibitor, Anti-PD1, Anti-CTLA-4, Myocarditis, Myositis, Myasthenia gravis, 3M
syndrome
Abbreviations: ASCO, American Society of Clinical Oncology; ECG, Electrocardiogram; CTLA-4, Cytotoxic Tlymphocyte-associated protein 4; ICI, Immune checkpoint inhibitor; IRAE, Immune-related adverse events; IVIG,
Intravenous immunoglobulin; LGE, Late gadolinium enhancement; LVEF, Left ventricular ejection fraction; MRI,
Magnetic resonance imaging; NT-proBNP, N-terminal pro-b-type natriuretic peptide; PD-1, Programmed cell death
protein 1; PD-L1, Programmed death ligand 1; PET-CT, Positron emission tomography-computed tomography; PE,
Pulmonary embolism; RCC, Renal cell carcinoma; SCLC, Small cell lung cancer; TACE, Transarterial
chemoembolization,
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Introduction

I

mmune checkpoint inhibitors (ICIs) have been
increasingly utilized in recent years owing to
their potent effect against a wide range of malignancies. Immune-related adverse events (IRAEs)
may occur as a result of autoimmunity from activated lymphocytes and the immune system. IRAEs
may affect virtually any organs such as skin, thyroid,
lungs, heart, gut, adrenal glands and nervous systems [1]. ICI myocarditis is a rare complication of
immunotherapy associated with high mortality [2].
Prompt initiation of potent immunosuppression is
necessary to reduce myocardial injury. We report
two cases of fulminant ICI myocarditis that were
refractory to potent immunosuppression to illustrate the challenges with managing this newly
emerged disease entity.

Case 1
A 71-year-old Chinese man was diagnosed to
have stage 4 cytotoxic T cell lymphoma, gastric
cancer, renal cell carcinoma (RCC) and small cell
lung cancer (SCLC) within a span of 1.5 years. After
he received distal radical gastrectomy for his gastric
cancer, systemic therapy for his remaining malignancies was started per a multidisciplinary team
decision, with priority given to his lymphoma. Prechemotherapy echocardiography in 2021 showed
normal left ventricular systolic function with structurally normal valves. He was subsequently given 5
cycles of SMILE (dexamethasone, methotrexate,
ifosfamide, L-asparaginase and etoposide) for his
lymphoma from April to December 2020. Reassessment positron emission tomography-computed
tomography (PET-CT) showed metabolic response
of his lymphoma but disease progression of his RCC
and SCLC. He then received the anti-programmed
cell death protein 1 (PD-1) antibody pembrolizumab
200 mg every 4 weeks as both maintenance therapy
for his lymphoma and ﬁrst-line treatment for his
SCLC and RCC. From March 2021 to January 2022,
he was given 13 doses of pembrolizumab, which
were well tolerated aside from grade 2 IRAE endocrinopathies (hypothyroidism and adrenal insufﬁciency) requiring thyroxine and hydrocortisone
replacements.
In February 2022, he was admitted for pleuritic
chest pain and left lower motor neuron type facial
nerve palsy. 12-lead electrocardiogram (ECG)
showed ST segment elevation and deep T wave
inversion over V2 to V6. Peak troponin T level during
hospital stay was 104 ng/L (Figure 3A)

Echocardiography showed impaired left ventricular
ejection fraction (LVEF) of 45% with no pericardial
effusion. Coronary angiogram and endomyocardial
biopsy were offered to the patient to rule out coronary artery disease and to obtain histological diagnosis. Nonetheless, patient declined both procedures
in view of advanced malignancy. Empirical treatment
with prednisolone 50 mg daily was given for possible
ICI related facial nerve palsy and myocarditis. One
month later, he was readmitted for atrial ﬁbrillation
with rapid ventricular rate and cardiogenic shock
requiring inotropic support, with a blood pressure on
admission of 90/60 mmHg and pulse rate of 135 beats
per minute. ECG showed atrial ﬁbrillation with
similar ST segment elevation over leads V2 to V6.
Initial troponin T was 2167 ng/L, creatinine kinase
was 284 U/L, N-terminal pro-b-type natriuretic
peptide (NT-proBNP) was 10,011 ng/L and lactate
was 5.8 mmol/L (Figure 3A) Echocardiography
showed a LVEF of 15% with global hypokinesia and
circumferential pericardial effusion up to 1.7 cm with
no tamponade effect. Coronary angiogram and
endomyocardial biopsy were again offered but
refused by the patient. Cardiac magnetic resonance
imaging (MRI) was performed and showed globally
hypokinetic left ventricle with LVEF 12% associated
with a left ventricular thrombus (Figure 1). In addition, extensive transmural myocardial inﬁltration
involving left and right ventricular apices and interventricular septum with positive late gadolinium
enhancement (LGE) of non-ischemic pattern was
present, compatible with myocarditis. In view of
compatible history and investigation ﬁndings, a
presumptive diagnosis of ICI peri-myocarditis was
made. Ischemic cardiomyopathy was considered less
likely in view of the non-ischemic patterns demonstrated on MRI. Alternative etiologies of heart failure
such as Takotsubo cardiomyopathy are uncommonly
associated with the constellation of thyroiditis,
adenitis and neuritis manifested in this patient. He
was started on pulse steroid with methylprednisolone 1000 mg daily for 3 days. From day 4 onwards,
methylprednisolone 1 mg/kg daily were given with
mycophenolate mofetil 1000 mg twice daily was later
added on day 6. He initially responded to treatment
with partial improvement of troponin T level to
295 ng/L on day 4 of pulse steroid, restoration of sinus
rhythm and reduction in pericardial effusion. However, his NT-proBNP remained markedly elevated at
> 16,000 ng/L and he remained inotrope-dependent
requiring concurrent noradrenaline and dopamine
infusions. He declined insertion of mechanical circulatory support and his condition progressively
deteriorated. Plasmapheresis was not considered
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owing to the unstable hemodynamic status. Since ICI
myocarditis is a T cell-driven condition, we administered 2 doses of the interleukin-2 (IL-2) receptor
antagonist basiliximab 20 mg IV, given 4 days apart.
Although experience with basiliximab is sparse in the
management of IRAEs, basiliximab has been successfully used as induction therapy in solid organ
transplantation and as salvage therapy for steroidrefractory graft-versus-host disease in haematopoietic stem cell transplantation. IL-2 receptor
blockade rapidly and effectively inhibits proliferation
of activated T cells. Experience from solid organ and
bone marrow transplantation suggests high tolerability and a low risk of infusions reactions or infective
complications, especially compared to alternative Tcell speciﬁc antibody therapies such as anti-thymocyte globulin or alemtuzumab. Nevertheless, he
further deteriorated and eventually succumbed 10
days after initiation of pulse steroid.

Case 2
A 75-year-old Chinese man, who was an ex-smoker
with hypertension, diabetes mellitus, hyperlipidemia, and benign prostatic hypertrophy, had
advanced hepatocellular carcinoma (aHCC) presenting with tumor rupture requiring urgent transarterial chemobolization (TACE) and pulmonary
embolism in late 2021. Anti-vascular endothelial
growth factor antibodies and tyrosine kinase inhibitor were considered extremely high risk in view of his
history of ruptured HCC. After discussion, he opted
for treatment with the anti-cytotoxic T-lymphocyteassociated protein 4 (CTLA-4) antibody ipilimumab
1 mg/kg and pembrolizumab 2 mg/kg, given in
combination every 3 weeks. Pre-ICI echocardiography showed normal left ventricular systolic function.
After six weeks of treatment with 2 doses of ICIs
given, he was admitted for further assessment with
complaints of 2 weeks' history of shortness of breath
and myalgia. On admission, he was afebrile with a
blood pressure of 174/84 mmHg, pulse rate of 116
beats per minute and fully preserved muscle power
over all four limbs (Medical Research Council grade
5/5). ECG showed sinus rhythm with no ST segment
or T wave changes. Initial blood tests showed
elevated creatine kinase 2515 U/L, troponin T
1350 ng/L and NT-proBNP 413 ng/L (Figure 3B)
Electromyography demonstrated features suggestive
of inﬂammatory myositis. Echocardiography showed
normal left ventricular cavity size and systolic function with no pericardial effusion. Cardiac MRI
showed patchy intramural delayed myocardial
enhancement at basal septal, inferior and mid
inferolateral left ventricular wall. Coronary
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angiogram only showed moderate stenosis over left
anterior descending artery (Figure 2), which was not
accountable for the persistently elevated troponin
level and the extensive myocardial involvement in
MRI. Endomyocardial biopsy showed diffuse inﬂammatory inﬁltration consisting of mostly polymorphs and occasional eosinophils. Expression of
programmed death-ligand 1 (PD-L1) was assessed
using PD-L1 (E1L3N) XP rabbit monoclonal antibody
(Cell Signaling Technology, USA). PD-L1 expression
was completely absent in cardiomyocytes, while
weak staining was observed in <5% inﬁltrating
lymphoid cells. No viral inclusion bodies, granuloma
or giant cells were detected. Microbiological investigations including polymerase chain reaction for
enterovirus, parvovirus B19, severe acute respiratory
syndrome coronavirus 2, and mycobacterium
tuberculosis nucleic acid were negative. Overall
histological diagnosis was consistent with polymorphic myocarditis.
With the overall clinical picture being compatible
with ICI-related myositis and myocarditis, he was
started on methylprednisolone 1000 mg for three
days on the second day of admission, followed by
methylprednisolone 1 mg/kg and mycophenolate
mofetil 1,000 mg twice daily. On day four of
admission, he developed severe dysphagia and type
2 respiratory failure requiring emergency intubation, mechanical ventilation and admission into the
intensive care unit. Physical examination demonstrated bilateral ptosis and fatiguability over eyelids
with intact limb power. Despite electromyography
of limbs with repetitive nerve stimulation showing
no evidence of signiﬁcant polyneuropathy or
neuromuscular junction disorder, the clinical features were highly suspicious of bulbar myasthenia
gravis and he was thus given intravenous immunoglobulin (IVIG) for 5 days followed by 3 sessions
of plasmapheresis as well.
After commencement of immunosuppressants,
his troponin T initially improved to 780 ng/L but
subsequent rebounded to 2573 ng/L as steroid was
tapered, after which tacrolimus was added on the
third week of admission. Reassessment echocardiography one week later showed preserved biventricular systolic function with LVEF of 60%.
Nevertheless, he remained dependent on nasogastric tube for feeding and mechanical ventilation for
respiratory support. After 2 weeks of intensive care
unit stay, the patient opted for comfort care and
requested withdrawal of invasive therapies. The
patient's autonomy was respected after thorough
discussion involving relatives, intensivists, and
neurologists. He eventually succumbed 28 days
after admission.
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Figure 1. Cardiac magnetic resonance imaging (MRI) of the left ventricle at (A) mid, and (B) apical levels demonstrated patchy non-ischemic inﬁltrates involving left ventricular apex, right ventricular apex and interventricular septum. (C) Late gadolinium enhancement was seen in the same
areas at left ventricular apical level. (D) Pericardial effusion with no tamponade and left ventricular apical thrombus were present.

Discussion

Figure 2. Coronary angiogram only revealed moderate left anterior
descending artery stenosis, which was not accountable for the persistently elevated troponin level and the extensive myocardial involvement
in magnetic resonance imaging.

Myocarditis is a rare but highly fatal IRAE, with a
reported incidence of 0.06e1.14% but mortality of
25e50% [2,3]. Due to the novelty and rarity of the
condition, relevant literature is scant. The majority
of ICI myocarditis appears to occur within the ﬁrst 3
months of ICI treatment, but onset of more than 18
months after ICI commencement has been documented. Patients with ICI myocarditis are more
likely to have received combination ICI therapies
with anti-CTLA-4 and anti-PD-1/L1 and suffering
from diabetes mellitus [2]. Common manifestations
include heart failure, complete heart block, ventricular arrhythmia and sudden death [2]. Intriguingly, although IRAEs frequently co-exist with each
other, ICI myocarditis seems to have particularly
strong associations with myositis and peripheral
nervous system disorders, most commonly myasthenia gravis. Our ﬁrst patient had lower-motor
neuron type facial nerve palsy with a similar onset
time to myocarditis, and our second patient had 3M
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Figure 3. Temporal relationship between immunosuppressive therapy and cardiac enzyme levels of the two patients. (A) Pulse steroid, mycophenolate
mofetil and basiliximab were given to the ﬁrst patient. (B) Pulse steroid, mycophenolate mofetil, tacrolimus and plasmapheresis were given to the
second patient. Abbreviations: FK, tacrolimus; IVIG: intravenous immunoglobulin; MMF: mycophenolate mofetil; MP50: methylprednisolone 50 mg
daily; P50: Prednisolone 50 mg daily; PX: plasmapheresis.

syndrome, comprising the classically described triad
of myocarditis, myositis and bulbar myasthenia
gravis [4e10].
To understand the pathophysiology of ICI
myocarditis, it is necessary to ﬁrst revisit the underlying mechanisms that prevent autoimmunity

against the heart [11e14]. T cells that are autoreactive against cardiomyocyte antigens undergo
negative selection during central tolerance induction of thymic development [15]. Nevertheless, some
T cells that are reactive against cardiac antigens are
not eliminated in the central tolerance phase, and
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peripheral tolerance mechanisms in heart draining
lymph nodes are responsible for inhibiting these
autoreactive T cells, via regulatory T cells and
CTLA-4 mediated block in costimulation [16]. In the
myocardium, tissue-based tolerance mechanisms
are also in place to further prevent autoimmunity
against the heart, including expression of PD-L1 by
cardiomyocytes. Binding of cardiomyocytes PD-L1
with lymphocyte PD1 blocks antigen and costimulator activation of T cells. Anti-PD1 therapeutics increases risk of autoimmune myocarditis by
inhibiting the PD1-PD-L1 axis and activating
effector T cells. Interestingly, contrary to the
expectation that T cell inﬁltration leads to increased
interferon-g secretion and upregulated PD-L1
expression in cardiomyocytes as a protective measure against autoimmunity [17,18], we observed no
PD-L1 expression by cardiomyocytes in immunohistochemistry studies of the second patient. The
relative lack of PD-L1 expression may further
exacerbate impairment of the PD1-PD-L1 axis. AntiCTLA-4 therapeutics impairs mechanisms in secondary lymphoid organs that prevent naïve autoreactive T cell activation. Furthermore, as CTLA-4 is
essential for regulatory T cell functions [19],
blockade of CTLA-4 impairs regulatory T cell and
increases risk of autoimmunity.
There is no international consensus regarding the
optimal immunosuppressants regimen in ICI
myocarditis. The 2018 American Society of Clinical
Oncology (ASCO) Guidelines recommends permanent discontinuation of ICI and initiation of steroid
at 1e2 mg/kg of prednisolone, and in patients
without immediate response, to administer pulse
steroid with methylprednisolone 1,000 mg per day
[20]. Alternatively, the French Working Group of
Cardio-Oncology recommend up-front pulse steroid with methylprednisolone 1000 mg per day [21],
as higher dose steroid was associated with lower
risk of MACE in a large cohort of patients with ICI
myocarditis [2]. A second agent is often required to
suppress myocardial inﬂammation, especially when
steroid is being tapered, with commonly recommended choices being mycophenolate, inﬂiximab or
anti-thymocyte globulin [20]. Agents including
abatacept [22], plasmapheresis [5], and IVIG [6] have
also been reported. In both of our patients, despite
administration of pulse steroid with methylprednisolone 1000 mg per day and mycophenolate as
second agent, normalization of troponin was not
achieved, though some response was noted. Available literature suggests that it is indeed not uncommon to have protracted troponin elevation
despite potent immunosuppression with 2e3
agents, even amongst patients who survived ICI

myocarditis [23]. As illustrated by our cases, the
high fatality of the condition is likely multi-factorial,
including difﬁculties inherent in diagnosing a rare
and novel entity, rapid progression to hemodynamic
failure, incessant myocardial damage despite potent
immunosuppression, the co-existence of debilitating
myositis and peripheral nervous system IRAEs and
ﬁnally side effects of profound immunosuppression.
Given the wide application of ICIs, clinical trials are
urgently needed to ﬁnd out the optimal therapy for
ICI myocarditis. ATRIUM (NCT05335928) and
ACHLYS (NCT05195645) are two on-going prospective studies investigating the use of abatacept
for treatment of ICI myocarditis. In addition, animal
models have been developed to facilitate pathophysiology studies and drug screening [24e27].
Early identiﬁcation of ICI myocarditis allows
prompt cessation of ICI and initiation of immunosuppressants, which may potentially improve cardiovascular outcome of these patients. Therefore, it
is imperative to determine to optimal strategy for
screening myocarditis among ICI recipients. Multiple strategies for screening ICI myocarditis have
been proposed, although no direct comparisons
exist [21]. The ﬁrst is symptom-driven, with patients
receiving cardiac investigations including ECG and
blood tests for troponin and BNP if they develop
symptoms or signs of heart failure or arrhythmia.
The second is systematic screening, by which all
patients receive regular ECGs and blood tests for
troponin and natriuretic peptide after each cycle of
ICI regardless of whether they are symptomatic. In a
recent study investigating the use of systematic
screening approach in 214 patients receiving ICI
alone or in combination, 11.2% had raised troponin I
and 1.4% had ICI myocarditis [28]. Nonetheless,
systematic screening is yet to be widely adopted as
more studies is required to clarify its impact on
prognosis and perform cost-beneﬁt analysis. Our
center is currently adopting symptom-driven strategy for identifying ICI myocarditis. ECG and cardiac
enzymes are performed if patients develop new
symptoms suggestive of possible cardiac etiologies.
Prompt reaction and joint care by oncologists and
cardiologists will be initiated if abnormalities are
detected.
It is crucial for clinicians to remain highly vigilant
in detection of this rare but lethal complication of
ICI. Nevertheless, alternative explanations of a new
onset heart failure and cardiogenic shock should
always be thoroughly investigated. Risk and beneﬁt
of invasive and non-invasive diagnostic modalities
must be carefully balanced as patients usually have
poor Eastern Cooperative Oncology Group (ECOG)
functional status on presentation and have
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complicated past medical history. Patient's hemodynamic stability must be taken into consideration
before invasive procedure. Conservative approach
with noninvasive imaging test was adopted in the
ﬁrst case. Speciﬁc attention to pattern of abnormalities on MRI, such as LGE patterns, is key to
exclude acute myocardial infarction with territorial
abnormalities.

[2]

[3]
[4]

Limitation
Our case series has several limitations. First,
endomyocardial biopsy and histological analysis of
the ﬁrst patient was not available as patient declined
the procedure. Diagnosis of myocarditis was established using clinical and MRI criteria. Second, as our
second patient passed away owing to type 2 respiratory failure, we could not assess the long-term
effect of myocarditis and immunosuppressive therapies he received.

[5]

[6]

[7]

[8]

Conclusion
ICI myocarditis is a rare but highly fatal IRAE,
with a disease course potentially refractory to
immunosuppression despite early recognition and
aggressive treatment. Further research is needed to
develop better treatment options and screening
strategies.

Acknowledgement

[9]

[10]

[11]

The authors would like to thank all clinicians who
contributed to managing the patients from this case
series.

[12]

Ethical statement

[13]

Written consent were obtained from both patients
for publication of case reports.

[14]
[15]

Conﬂict of Interest
The authors report no conﬂict of interest.

Funding

[16]
[17]

This study was partly supported by Li Shu Fan
Medical Fellowship, by Li Ka Shing Faculty of
Medicine, The University of Hong Kong, and Hong
Kong Sanatorium & Hospital, Hong Kong SAR.

[19]

References

[20]

[1] Lui DTW, Lee CH, Tang V, Fong CHY, Lee ACH, Chiu JWY,
et al. Thyroid immune-related adverse events in patients
with cancer treated with anti-PD1/anti-CTLA4 immune

[18]

141

checkpoint inhibitor combination: clinical course and outcomes. Endocr Pract 2021;27:886e93.
Mahmood SS, Fradley MG, Cohen JV, Nohria A,
Reynolds KL, Heinzerling LM, et al. Myocarditis in patients
treated with immune checkpoint inhibitors. J Am Coll Cardiol 2018;71:1755e64.
Johnson DB, Balko JM, Compton ML, Chalkias S, Gorham J,
Xu Y, et al. Fulminant myocarditis with combination immune
checkpoint blockade. N Engl J Med 2016;375:1749e55.
Valenti-Azcarate R, Esparragosa Vazquez I, Toledano
Illan C, Idoate Gastearena MA, Gallego Perez-Larraya J.
Nivolumab and Ipilimumab-induced myositis and myocarditis mimicking a myasthenia gravis presentation. Neuromuscul Disord 2020;30:67e9.
Wakeﬁeld C, Shultz C, Patel B, Malla M. Life-threatening
immune checkpoint inhibitor-induced myocarditis and
myasthenia gravis overlap syndrome treated with abatacept:
a case report. BMJ Case Rep 2021:14.
Yanase T, Moritoki Y, Kondo H, Ueyama D, Akita H, Yasui T.
Myocarditis and myasthenia gravis by combined nivolumab
and ipilimumab immunotherapy for renal cell carcinoma: a
case report of successful management. Urol Case Rep 2021;
34:101508.
Rajendram P, Torbic H, Duggal A, Campbell J, Hovden M,
Dhawan V, et al. Critically ill patients with severe immune
checkpoint inhibitor related neurotoxicity: a multi-center
case series. J Crit Care 2021;65:126e32.
Rhee JY, Torun N, Neilan TG, Guidon AC. Consider
myocarditis when patients treated with immune checkpoint
inhibitors present with ocular symptoms. Oncol 2022;27:
e402e5.
Wai Siu DH, O'Neill RS, Harris CA, Wang J, Ardolino L,
Downton T, et al. Immune checkpoint inhibitor-induced
myocarditis, myositis, myasthenia gravis and transaminitis: a
case series and review. Immunotherapy 2022;14:511e20.
Bai J, Li D, Yang P, Xu K, Wang Y, Li Q, et al. Camrelizumabrelated myocarditis and myositis with myasthenia gravis: a
case report and literature review. Front Oncol 2021;11:
778185.
Dong H, Qi Y, Kong X, Wang Z, Fang Y, Wang J. PD-1/PD-L1
inhibitor-associated myocarditis: epidemiology, characteristics, diagnosis, treatment, and potential mechanism. Front
Pharmacol 2022;13:835510.
Palaskas N, Lopez-Mattei J, Durand JB, Iliescu C, Deswal A.
Immune checkpoint inhibitor myocarditis: pathophysiological characteristics, diagnosis, and treatment. J Am Heart
Assoc 2020;9:e013757.
Grabie N, Lichtman AH, Padera R. T cell checkpoint regulators in the heart. Cardiovasc Res 2019;115:869e77.
Varricchi G, Galdiero MR, Marone G, Criscuolo G, Triassi M,
Bonaduce D, et al. Cardiotoxicity of immune checkpoint inhibitors. ESMO Open 2017;2:e000247.
Hogquist KA, Baldwin TA, Jameson SC. Central tolerance:
learning self-control in the thymus. Nat Rev Immunol 2005;5:
772e82.
Mueller DL. Mechanisms maintaining peripheral tolerance.
Nat Immunol 2010;11:21e7.
Latchman Y, Wood CR, Chernova T, Chaudhary D, Borde M,
Chernova I, et al. PD-L2 is a second ligand for PD-1 and
inhibits T cell activation. Nat Immunol 2001;2:261e8.
Hardy T, Yin M, Chavez JA, Ivanov I, Chen W, Nadasdy T,
et al. Acute fatal myocarditis after a single dose of anti-PD-1
immunotherapy, autopsy ﬁndings: a case report. Cardiovasc
Pathol 2020;46:107202.
Wing K, Yamaguchi T, Sakaguchi S. Cell-autonomous and
-non-autonomous roles of CTLA-4 in immune regulation.
Trends Immunol 2011;32:428e33.
Brahmer JR, Lacchetti C, Schneider BJ, Atkins MB, Brassil KJ,
Caterino JM, et al. Management of immune-related adverse
events in patients treated with immune checkpoint inhibitor
therapy: American society of clinical Oncology clinical
practice guideline. J Clin Oncol 2018;36:1714e68.

142

J HK COLL CARDIOL 2022;29(3):135e142

[21] Thuny F, Alexandre J, Salem JE, Mirabel M, Dolladille C,
Cohen-Solal A, et al. Management of immune checkpoint inhibitor-induced myocarditis: the French working group's plea
for a pragmatic approach. JACC CardioOncol 2021;3:157e61.
[22] Jespersen MS, Fano S, Stenor C, Moller AK. A case report of
immune checkpoint inhibitor-related steroid-refractory
myocarditis and myasthenia gravis-like myositis treated with
abatacept and mycophenolate mofetil. Eur Heart J Case Rep
2021;5:ytab342.
[23] Miyauchi Y, Naito H, Tsunemori H, Tani R, Hasui Y,
Miyake Y, et al. Myocarditis as an immune-related adverse
event following treatment with ipilimumab and nivolumab
combination therapy for metastatic renal cell carcinoma: a
case report. J Med Case Rep 2021;15:508.
[24] Liu SY, Huang WC, Yeh HI, Ko CC, Shieh HR, Hung CL,
et al. Sequential blockade of PD-1 and PD-L1 causes fulminant cardiotoxicity-from case report to mouse model validation. Cancers 2019;11.

[25] Wei SC, Meijers WC, Axelrod ML, Anang NAS,
Screever EM, Wescott EC, et al. A genetic mouse model recapitulates
immune
checkpoint
inhibitor-associated
myocarditis and supports a mechanism-based therapeutic
intervention. Cancer Discov 2021;11:614e25.
[26] Wang J, Okazaki IM, Yoshida T, Chikuma S, Kato Y,
Nakaki F, et al. PD-1 deﬁciency results in the development
of fatal myocarditis in MRL mice. Int Immunol 2010;22:
443e52.
[27] Tay WT, Fang YH, Beh ST, Liu YW, Hsu LW, Yen CJ, et al.
Programmed cell death-1: programmed cell death-ligand 1
interaction protects human cardiomyocytes against T-cell
mediated inﬂammation and apoptosis response in vitro. Int J
Mol Sci 2020:21.
[28] Waliany S, Neal JW, Reddy S, Wakelee H, Shah SA,
Srinivas S, et al. Myocarditis surveillance with high-sensitivity troponin I during cancer treatment with immune
checkpoint inhibitors. JACC CardioOncol 2021;3:137e9.

